So low ... so far so good: neurocognitive impact of lowering LDL-C levels with PCSK9 inhibitors

被引：35
|
作者：
Gencer, Baris [1 ]
Mach, Francois [1 ]
机构：
[1] Geneva Univ Hosp, Dept Specialties Med, Cardiol Div, Rue Gabrielle Perret Gentil 4, CH-1211 Geneva 14, Switzerland
来源：
EUROPEAN HEART JOURNAL | 2018年 / 39卷 / 05期
基金：
瑞士国家科学基金会;
关键词：
COGNITIVE FUNCTION; FOURIER TRIAL; OLDER-ADULTS; CHOLESTEROL; EFFICACY; SAFETY; METAANALYSIS; EVOLOCUMAB; STATINS; DISEASE;
D O I：
10.1093/eurheartj/ehx742
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
This editorial refers to 'No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: meta-analysis of individual patient data'+, by P.D. Harvey et al., on page 374.
引用
收藏
页码：382 / 384
页数：3
相关论文
共 50 条
  • [41] Correction to: The Effect of PCSK9 Inhibitors on LDL-C Target Achievement in Patients with Homozygous Familial Hypercholesterolemia: A Retrospective Cohort Analysis
    Awad Alshahrani
    Naji Kholaif
    Mutaz Al-Khnifsawi
    Hawazen Zarif
    Moeber Mahzari
    Advances in Therapy, 2024, 41 : 2083 - 2083
  • [42] VARIANTS IN THE C-TERMINAL REGION OF PCSK9 AFFECT LDL-C LEVELS IN A BLACK SOUTH AFRICAN POPULATION (THE PURE STUDY)
    Van Zyl, T.
    Conradie, K. R.
    Jerling, J. C.
    Towers, G. W.
    ANNALS OF NUTRITION AND METABOLISM, 2013, 63 : 408 - 409
  • [43] Impact of PCSK9 inhibitors Alirocumab and Evolocumab on total & LDL cholesterol in clinical practice
    Capps, N.
    ATHEROSCLEROSIS SUPPLEMENTS, 2017, 28 : E13 - E13
  • [44] Patient and Physician Perspectives on Mode of Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels
    Roth, Eli M.
    Bujas-Bobanovic, Maja
    Louie, Michael J.
    Cariou, Bertrand
    CLINICAL THERAPEUTICS, 2015, 37 (09) : 1945 - 1954
  • [45] Reduction of circulating PCSK9 and LDL-C levels by liver-specific knockdown of HNF1α in normolipidemic mice
    Shende, Vikram Ravindra
    Wu, Minhao
    Singh, Amar Bahadur
    Dong, Bin
    Kan, Chin Fung Kelvin
    Liu, Jingwen
    JOURNAL OF LIPID RESEARCH, 2015, 56 (04) : 801 - 809
  • [46] Genetic Variation in APOB, PCSK9, and ANGPTL3 in Carriers of Pathogenic Autosomal Dominant Hypercholesterolemic Mutations with Unexpected Low LDL-C Levels
    Huijgen, Roeland
    Sjouke, Barbara
    Vis, Kelly
    de Randamie, Janine S. E.
    Defesche, Joep C.
    Kastelein, John J. P.
    Hovingh, G. Kees
    Fouchier, Sigrid W.
    HUMAN MUTATION, 2012, 33 (02) : 448 - 455
  • [47] LDL cholesterol-lowering therapies: emphasis on proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors
    Sabatel-Perez, F.
    Garcia-Ropero, A.
    Santos-Gallego, G.
    Zafar, M. Urooj
    Badimon, J. J.
    DRUGS OF TODAY, 2019, 55 (05) : 329 - 344
  • [48] Impact of the first nine months of revised infective endocarditis prophylaxis guidelines at a university hospital: So far so good
    Rogers, Adam M.
    Schiller, Nelson B.
    JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY, 2008, 21 (06) : 775 - 775
  • [49] Thyroid stimulating hormone exhibits the impact on LDLR/LDL-c via up-regulating hepatic PCSK9 expression
    Gong, Yingyun
    Ma, Yizhe
    Ye, Zhengqin
    Fu, Zhenzhen
    Yang, Panpan
    Gao, Beibei
    Guo, Wen
    Hu, Dandan
    Ye, Jingya
    Ma, Shuai
    Zhang, Fan
    Zhou, Li
    Xu, Xinyu
    Li, Zhong
    Yang, Tao
    Zhou, Hongwen
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2017, 76 : 32 - 41
  • [50] SIRNA TO PCSK9 IN PATIENTS WITH HIGH CARDIOVASCULAR RISK AND ELEVATED LDL-C: THE ORION 1 TRIAL
    Ray, Kausik K.
    Landmesser, Ulf
    Leiter, Lawrence A.
    Kallend, David
    Wijngaard, Peter L. J.
    Wright, R. Scott
    Kastelein, John J. P.
    ATHEROSCLEROSIS, 2017, 263 : E9 - E10
12345